首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL29 |
| Uniprot No | Q8IU54 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-200aa |
| 氨基酸序列 | MAAAWTVVLV TLVLGLAVAG PVPTSKPTTT GKGCHIGRFK SLSPQELASF KKARDALEES LKLKNWSCSS PVFPGNWDLR LLQVRERPVA LEAELALTLK VLEAAAGPAL EDVLDQPLHT LHHILSQLQA CIQPQPTAGP RPRGRLHHWL HRLQEAPKKE SAGCLEASVT FNLFRLLTRD LKYVADGNLC LRTSTHPEST |
| 预测分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-29重组蛋白的3篇代表性文献概览：
1. **《Recombinant Human Interferon Lambda 1 (IL-29) Exhibits Antiviral Activity Against Hepatitis C Virus》**
- 作者：Robek MD, Boyd BS, Chisari FV
- 摘要：该研究首次证明了重组人IL-29(IFN-λ1)在体外对丙型肝炎病毒(HCV)复制的抑制作用，揭示了其通过激活JAK-STAT信号通路诱导抗病毒蛋白表达，提示IL-29可能作为HCV治疗的潜在候选药物。
2. **《IL-29 Enhances TLR3-Mediated Antiviral Cytokine Response in Human Epithelial Cells》**
- 作者：Dellgren C, Gad HH, Hamming OJ, et al.
- 摘要：研究发现重组IL-29能协同Toll样受体3(TLR3)配体增强呼吸道上皮细胞的抗病毒免疫反应，促进IFN-β和ISGs(干扰素刺激基因)表达，为IL-29在呼吸道病毒感染(如流感)中的免疫调节作用提供了机制解释。
3. **《Production and Characterization of Functional Recombinant IL-29 in a Mammalian Expression System》**
- 作者：Zhang Y, Wang L, Li J, et al.
- 摘要：该文优化了IL-29在HEK293细胞中的重组表达工艺，通过亲和层析获得高纯度蛋白，并验证其诱导MxA蛋白表达和抑制水泡性口炎病毒(VSV)感染的能力，为大规模生产功能性IL-29提供了技术参考。
*注：以上为模拟文献示例，实际研究中建议通过PubMed或Web of Science检索最新论文。*
Interleukin-29 (IL-29), also known as interferon lambda 1 (IFN-λ1), is a cytokine belonging to the type III interferon family. It was discovered in the early 2000s alongside IL-28A (IFN-λ2) and IL-28B (IFN-λ3), sharing structural and functional similarities with type I interferons but differing in receptor specificity. IL-29 signals through a unique heterodimeric receptor complex composed of IFNLR1 (IL-28Rα) and IL-10Rβ, which is predominantly expressed on epithelial cells, hepatocytes, and certain immune cells. This restricted receptor distribution allows IL-29 to mediate targeted immune responses while potentially minimizing systemic inflammation, a limitation often observed with type I interferons.
Functionally, IL-29 plays a critical role in antiviral defense, particularly against RNA viruses like hepatitis C virus (HCV) and influenza. It activates the JAK-STAT signaling pathway, inducing interferon-stimulated genes (ISGs) that establish an antiviral state in infected and neighboring cells. Beyond viral immunity, IL-29 modulates adaptive immunity by influencing dendritic cell maturation, T-cell differentiation, and antibody production. Its role in autoimmune diseases and cancer is under investigation, with studies suggesting both pro-inflammatory and regulatory effects depending on context.
Recombinant IL-29 protein, produced via bacterial or mammalian expression systems, is widely used in research to explore these biological activities. Therapeutic applications are being explored, particularly for chronic viral infections and cancers unresponsive to type I interferons. However, challenges remain in optimizing delivery methods and understanding tissue-specific effects. As a relatively newly characterized cytokine, IL-29 continues to be a focus for unraveling its nuanced roles in immunity and disease pathogenesis.
×
